Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Free Report) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,650,000 shares, an increase of 159.8% from the September 30th total of 1,020,000 shares. Based on an average trading volume of 405,900 shares, the short-interest ratio is currently 6.5 days.
Oncolytics Biotech Stock Down 2.4 %
NASDAQ:ONCY traded down $0.03 on Friday, reaching $1.22. 430,465 shares of the company’s stock traded hands, compared to its average volume of 326,325. The stock has a 50-day simple moving average of $1.04 and a 200-day simple moving average of $1.05. The firm has a market cap of $93.10 million, a PE ratio of -4.07 and a beta of 1.79. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.80.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. During the same period in the prior year, the firm earned ($0.09) EPS. On average, equities analysts anticipate that Oncolytics Biotech will post -0.29 earnings per share for the current year.
Institutional Investors Weigh In On Oncolytics Biotech
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Thursday, September 19th.
View Our Latest Report on Oncolytics Biotech
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Using the MarketBeat Dividend Tax Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Dividend Champions? How to Invest in the Champions
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.